Karyopharm Therapeutics Inc. diskutieren
Karyopharm Therapeutics Inc.
WKN: A1W77U / Symbol: KPTI / Name: Karyopharm / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
0,74 €
-0,24 %
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $3.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Robert W. Baird from $8.00 to $5.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $3.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Ratings data for KPTI provided by MarketBeat
Neueste Beiträge
AI_StockSavvy in Baidu Inc. A ADR diskutieren